SCHEMBL2653368

SCHEMBL2653368

COC(=O)c1cc(OC(C)=O)c2ccoc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.44
NPC1 O15118 1/20 0.44
PKM P14618 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KCNA3 P22001 2/20 0.42
TSHR P16473 3/20 0.40
MAPT P10636 1/20 0.40
KDM4E B2RXH2 3/20 0.40
GAA P10253 2/20 0.40
ALDH1A1 P00352 1/20 0.40
TOP1 P11387 3/20 0.38
KMT2A Q03164 3/20 0.38
POLB P06746 2/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
CREBBP Q92793 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18585480 0.87 KDM4E (0.48) SMN1; SMN2KCNA3TSHRMAPTKDM4E
SCHEMBL18585715 0.85 TSHR (0.53) RAB9APKMSMN1; SMN2KCNA3TSHR
SCHEMBL2813926 0.85 KDM4E (0.44) RAB9ANPC1SMN1; SMN2KCNA3TSHR
SCHEMBL31359551 0.79 LMNA (0.53) SMN1; SMN2KCNA3MAPTKDM4EGAA
SCHEMBL2653802 0.79 LMNA (0.53) SMN1; SMN2KCNA3MAPTKDM4EGAA
SCHEMBL10069354 0.79 KDM4E (0.42) SMN1; SMN2KCNA3TSHRMAPTKDM4E
SCHEMBL2654537 0.77 KDM4E (0.43) RAB9ANPC1PKMSMN1; SMN2TSHR
SCHEMBL31359519 0.77 HPGD (0.55) RAB9ANPC1SMN1; SMN2KCNA3MAPT
SCHEMBL21438057 0.76 KDM4E (0.42) RAB9ANPC1PKMSMN1; SMN2TSHR
SCHEMBL15012676 0.74 HTT (0.48) RAB9ANPC1PKMSMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7709505-B2 Benzofuran derivatives, process for their preparation and intermediates thereof ASTRAZENECA AB (SE) 2010-05-04 US disclosed
EP-1578745-B1 BENZOFURAN DERIVATivES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF ASTRAZENECA AB (SE) 2007-11-14 EP disclosed
US-20060058353-A1 Benzofuran derivatives, process for their preparation and intermediates thereof ASTRAZENECA AB (SE) 2006-03-16 US disclosed
EP-1578745-A1 BENZOFURAN DERIVATES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF Astrazeneca AB (SE) 2005-09-28 EP disclosed
WO-2004046139-A1 BENZOFURAN DERIVATES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF ASTRAZENECA AB (SE) 2004-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058353-A1 Benzofuran derivatives, process for their preparation and intermediates thereof GCK, PDK2, GCKR RAB9A 4430/4885NPC1 2891/4885PKM 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.